Last reviewed · How we verify
BRM421 Ophthalmic Solution
BRM421 is an ophthalmic solution designed to treat ocular surface disease, likely through anti-inflammatory or lubricating mechanisms.
BRM421 is an ophthalmic solution designed to treat ocular surface disease, likely through anti-inflammatory or lubricating mechanisms. Used for Dry eye disease or ocular surface disease (presumed, based on ophthalmic formulation).
At a glance
| Generic name | BRM421 Ophthalmic Solution |
|---|---|
| Sponsor | BRIM Biotechnology Inc. |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
As a Phase 3 ophthalmic formulation, BRM421 is being developed for topical ocular administration. The specific molecular mechanism is not publicly disclosed in available sources, but ophthalmic solutions in clinical development typically target inflammatory pathways, mucin production, or aqueous tear film stability to address dry eye disease or related ocular surface conditions.
Approved indications
- Dry eye disease or ocular surface disease (presumed, based on ophthalmic formulation)
Common side effects
Key clinical trials
- BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency
- A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease (PHASE2)
- Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects. (PHASE3)
- Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment (PHASE2, PHASE3)
- Safety and Efficacy of BRM421 for Dry Eye Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |